Answers are grounded in this paper and cite their sources.
In this ongoing, open-label phase 3b/4 study, JN.1- and KP.2-encoding monovalent mRNA-1273 vaccines elicited robust neutralizing antibody responses against vaccine-matched variants and cross-neutralized currently circulating JN.1 subvariants (KP.3.1.1, XEC, LP.8.1) in adults with previous COVID-19 mRNA vaccination, with reduced cross-neutralization observed against all subvariants tested. No safety concerns were identified.
No takes yet. Share an insight, caveat, or question.
Figueroa et al. (2025) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: